Skip to main content

Table 1 Expression of EBAG9 and 22-1-1 on cancer cell lines.

From: Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker

Cell line Origin 22-1-1 expression Flow cytometry EBAG9 expression Immunoblot
MCF-7 breast carcinoma ++ +++
K562 chronic myelogenous leukemia - +++
Jurkat T cell leukemia +++ +++
Colo-205 colorectal carcinoma - +++
SiSo cervix carcinoma + +++
CAL-51 breast carcinoma - +++
T-47D breast carcinoma - +++
ZR-75-1 breast carcinoma - +++
HBL-100 breast carcinoma - +++
U-266 multiple myeloma - ++
CaCo-2 colon carcinoma - ++
MDA-MB-461 breast carcinoma - +
HEK293 A embryonal kidney - +
U-373 glioblastoma-astrocytoma - +
L-1236 Hodgkin's lymphoma - +
H-184 A1 normal breast - +
SW-480 colon carcinoma - +
MDA-MB-468 breast carcinoma - +
  1. Expression of antigen on the cell surface was determined by incubation with 22-1-1 antibody and analysed by flow cytometry. Expression of EBAG9 was determined by immunoblot using the anti-EBAG9 serum. (+++, very high expression, ++, high expression, +, intermediate expression, -, no expression).